Skip to content
Screener

Vaxcyte, Inc. PCVX Acquired manufacturing rights

Acquired manufacturing rights at other companies

FreightCar America logo
FreightCar AmericaRAIL
$0-100%
Jaguar Uranium logo
Jaguar UraniumJAGU
$60K
Jaguar Uranium logo
Jaguar UraniumJAGU
$60K
Uranium Energy logo
Uranium EnergyUEC
$0
American Battery Technology Company logo
American Battery Technology CompanyABAT
$818.01K
Solitario Resources logo
Solitario ResourcesXPL
$7.75K-43.6%

Segments

By segment

See full
Reportable Segment$0

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept pcvx:AcquiredManufacturingRightsExpense.

The source filing: Vaxcyte, Inc.’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:37 PM EST
Fiscal year
FY2025
Accession
0001649094-26-000007
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Operating expenses:
Research and development$794,306$476,644$332,341
Acquired manufacturing rights (Note 7)75,000
General and administrative129,36992,90260,700
Total operating expenses923,675569,546468,041
Loss from operations(923,675)(569,546)(468,041)
Other income, net:
Interest income119,718109,99462,907

Item 8. Consolidated Financial Statements and Supplementary Data.

FAQ

What is Vaxcyte, Inc.'s acquired manufacturing rights?
Vaxcyte, Inc. (PCVX) reported acquired manufacturing rights of $0 in Q4 2025.
What is the long-term trend for Vaxcyte, Inc.'s acquired manufacturing rights?
Over 3 years (2022 to 2025), Vaxcyte, Inc.'s acquired manufacturing rights has grown at a -100.0% compound annual growth rate (CAGR), from $23M to $0.
What does acquired manufacturing rights mean?
This metric represents the costs associated with obtaining the legal or contractual rights to utilize specific manufacturing processes, technologies, or facilities. It reflects the company's strategic investment in securing production capabilities necessary to scale vaccine candidates from development to commercialization. Monitoring this expense helps investors assess the capital intensity of the firm's manufacturing strategy and its progress toward establishing a robust supply chain.

Ask your AI about Vaxcyte, Inc.'s acquired manufacturing rights.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude